Considering the high mutation rates of CREBBP and EP300 in DLBCL and follicular lymphoma (FL), the two most common types of NHL, and the prognostic value of these two genes in FL (M7-FLIPI)44, the findings of our study provide insights for the development of more effective targeted therapies as well as novel combination treatments that may benefit a large group of patients. The gene discussed is EP300; the disease is non-Hodgkin lymphoma.